Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved a non-qualified stock option to purchase 4,000 shares for a newly hired employee on March 11, 2025.
The grant, issued through Aligos' 2024 Inducement Plan, serves as an employment inducement and has an exercise price matching the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments, contingent on continued employment.
Aligos Therapeutics (Nasdaq: ALGS), un'azienda biofarmaceutica in fase clinica specializzata in malattie epatiche e virali, ha annunciato un'assegnazione di incentivo ai sensi della Regola di quotazione Nasdaq 5635(c)(4). Il Comitato per la Compensazione dell'azienda ha approvato un'opzione su azioni non qualificata per l'acquisto di 4.000 azioni per un nuovo dipendente il 11 marzo 2025.
L'assegnazione, emessa attraverso il Piano di Incentivo 2024 di Aligos, funge da incentivo all'occupazione e ha un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di Aligos nella data di assegnazione. Le azioni matureranno nel corso di quattro anni, con il 25% che matura dopo il primo anno e la parte restante che matura in rate mensili uguali, a condizione di continuare l'impiego.
Aligos Therapeutics (Nasdaq: ALGS), una compañía biofarmacéutica en etapa clínica especializada en enfermedades hepáticas y virales, ha anunciado una concesión de incentivo bajo la Regla de Listado Nasdaq 5635(c)(4). El Comité de Compensación de la compañía aprobó una opción de acciones no calificadas para la compra de 4,000 acciones para un nuevo empleado el 11 de marzo de 2025.
La concesión, emitida a través del Plan de Incentivo 2024 de Aligos, sirve como un incentivo de empleo y tiene un precio de ejercicio que coincide con el precio de cierre de las acciones ordinarias de Aligos en la fecha de la concesión. Las acciones se adquirirán durante cuatro años, con el 25% adquiriéndose después del primer año y el resto adquiriéndose en cuotas mensuales iguales, condicionado a la continuación del empleo.
Aligos Therapeutics (Nasdaq: ALGS)는 간 및 바이러스 질환을 전문으로 하는 임상 단계의 생명공학 회사로, Nasdaq 상장 규정 5635(c)(4)에 따라 유인 보조금을 발표했습니다. 회사의 보상위원회는 2025년 3월 11일에 새로 채용된 직원에게 4,000주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
이 보조금은 Aligos의 2024 유인 계획을 통해 발급되며, 고용 유인을 제공하고 보조금 날짜의 Aligos 보통주 종가와 일치하는 행사 가격을 가지고 있습니다. 주식은 4년에 걸쳐 분할되어 부여되며, 첫 해가 지나면 25%가 부여되고 나머지는 계속 고용되는 조건으로 매월 동일한 금액으로 부여됩니다.
Aligos Therapeutics (Nasdaq: ALGS), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies hépatiques et virales, a annoncé une attribution d'incitation conformément à la règle de cotation Nasdaq 5635(c)(4). Le Comité de Rémunération de l'entreprise a approuvé une option d'achat d'actions non qualifiée pour l'acquisition de 4 000 actions pour un nouvel employé le 11 mars 2025.
L'attribution, émise dans le cadre du Plan d'Incitation 2024 d'Aligos, sert d'incitation à l'emploi et a un prix d'exercice correspondant au prix de clôture des actions ordinaires d'Aligos à la date de l'attribution. Les actions seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et le reste acquis en paiements mensuels égaux, sous réserve de la poursuite de l'emploi.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Leber- und Viruskrankheiten spezialisiert hat, hat eine Anreizgewährung gemäß der Nasdaq-Listing-Regel 5635(c)(4) angekündigt. Der Vergütungsausschuss des Unternehmens genehmigte am 11. März 2025 eine nicht qualifizierte Aktienoption zum Kauf von 4.000 Aktien für einen neu eingestellten Mitarbeiter.
Die Gewährung, die im Rahmen des Aligos 2024 Anreizplans ausgegeben wurde, dient als Beschäftigungsanreiz und hat einen Ausübungspreis, der dem Schlusskurs der Aligos-Stammaktien am Gewährungsdatum entspricht. Die Aktien werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach dem ersten Jahr fällig werden und der verbleibende Teil in gleichen monatlichen Raten fällig wird, abhängig von der Fortsetzung der Beschäftigung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company’s stock (the “Inducement Grant”) to a newly hired employee on March 11, 2025 (the “Grant Date”), in connection with the commencement of employment.
The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grant has an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
What are the vesting terms for Aligos Therapeutics' (ALGS) March 2025 inducement grant?
How many shares were included in Aligos Therapeutics' (ALGS) March 2025 inducement grant?
What is the exercise price for ALGS's March 2025 inducement grant?
When was the ALGS inducement grant approved and under what regulation?
